WO2012132774A1 - Dispositif d'administration d'une composition médicamenteuse - Google Patents

Dispositif d'administration d'une composition médicamenteuse Download PDF

Info

Publication number
WO2012132774A1
WO2012132774A1 PCT/JP2012/055584 JP2012055584W WO2012132774A1 WO 2012132774 A1 WO2012132774 A1 WO 2012132774A1 JP 2012055584 W JP2012055584 W JP 2012055584W WO 2012132774 A1 WO2012132774 A1 WO 2012132774A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
bag
insert
outer needle
application device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/055584
Other languages
English (en)
Japanese (ja)
Inventor
恭大 木村
直孝 千野
敬亮 吉野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to JP2013507313A priority Critical patent/JP5963744B2/ja
Publication of WO2012132774A1 publication Critical patent/WO2012132774A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0097—Catheters; Hollow probes characterised by the hub
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0056—Catheters; Hollow probes characterised by structural features provided with an antibacterial agent, e.g. by coating, residing in the polymer matrix or releasing an agent out of a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings

Definitions

  • the present invention applies a pharmaceutical composition in a gap between an inserted body inserted and placed in a living body and a living tissue, and prevents the entry of foreign substances such as bacteria and dirt from the outside into the gap.
  • a pharmaceutical composition in a gap between an inserted body inserted and placed in a living body and a living tissue, and prevents the entry of foreign substances such as bacteria and dirt from the outside into the gap.
  • a gap may be formed between the insert and a living tissue (for example, the body surface), and microorganisms (for example, bacteria resident in the skin) or If foreign matter such as dirt enters, there is a risk of causing infection or inflammation.
  • a living tissue for example, the body surface
  • microorganisms for example, bacteria resident in the skin
  • JP-A-9-94299 JP 2008-220633 A Japanese Patent No. 3046623
  • the treatment of applying such a dressing or pad to the insert or its peripheral part can obtain a certain effect for prevention of infection and inflammation.
  • the outer diameter of the insert when sticking the pad, the outer diameter of the insert must be smaller than the inner diameter of the opening established in the pad, and it may be difficult to select the size of the insert or pad opening. There is also a problem that the entire circumference or azimuth of the insert cannot be reliably closed.
  • the present invention has been made in order to solve the above-described problems.
  • the gap formed between the insert and the living tissue is reliably closed with the pharmaceutical composition, and foreign matters such as bacteria and dirt enter the gap from the outside.
  • An object of the present invention is to provide a device for applying a pharmaceutical composition that can prevent the risk of infection and significantly reduce the risk of infection and inflammation.
  • the drug composition application device of the present invention that achieves the above object is a drug composition application device that applies a drug composition to a gap between an insert inserted into a living body and a living tissue, A housing part that is provided in the insert and contains a drug composition that has antibacterial properties and fluidity with respect to the living tissue; an unsealing part that can open the housing part; and the housing part It is characterized in that the drug composition that flows out along with opening is guided to the gap by flowing along at least a part of the insert.
  • the present invention provides an insertion body containing a drug composition having antibacterial properties and fluidity with respect to a living tissue in the insert, and the drug composition flowing out when the container is opened is Since it is guided at least partially through the gap between the insert and the living tissue, the insertion portion that is the entrance portion of the gap is simply opened by inserting the insert into the living body.
  • the finger touches the adhesive part, and the adhesive part is contaminated by bacteria, blood, dirt, etc. adhering to the finger, but around the insertion part without touching the adhesive part during insertion.
  • the portion can be covered with a pharmaceutical composition.
  • the operator can significantly reduce the risk of foreign substances such as bacteria and dirt entering the gap formed between the insert and the living tissue and causing infection and inflammation. .
  • the housing part is constituted by a bag-like bag capable of enclosing the pharmaceutical composition
  • the opening part is constituted by a weak seal part having a weak seal strength provided in at least a part of the bag. Therefore, the pharmaceutical composition can be caused to flow out toward the gap between the insert and the living tissue by the rupture of the weak seal portion.
  • the insertion operation of the insert and the rupture operation of the weak seal portion can be performed independently. It becomes effective when it is set at a desired position after repeating the insertion operation. After inserting and setting the insertion body, a predetermined amount of the pharmaceutical composition can be appropriately applied by one rupture operation, and the convenience of the procedure is improved. Greatly improved.
  • the invention of claim 3 divides the inside of the bag into a plurality of storage chambers by partition walls, stores different drug compositions in each storage chamber, and mixes the plurality of drug compositions by rupture operation of the bag.
  • pharmaceutical compositions that require different properties such as antibacterial properties and adhesiveness can be set without problems, and the mixed pharmaceutical composition can be used to close the gap between the living tissue and the insertion member.
  • coat so that the peripheral part of an insertion part may be covered widely, and the generation
  • the pharmaceutical composition mixed by a single crushing operation can be applied to the gap or the peripheral portion of the insertion portion.
  • the bag is composed of a plurality of bags each containing different drug compositions, and the drugs having different properties are mixed by the rupture operation of the weak seal portion of each bag.
  • the bag is easy to break and the convenience of the procedure is improved.
  • the insert includes an insertion member to be inserted into the living body, and a large diameter portion provided on the proximal end side of the insertion member, and the accommodating portion is provided in the large diameter portion. Therefore, when performing a normal procedure, i.e., a procedure for inserting the insertion member to the vicinity of the large diameter portion, in a state where the insertion member is inserted, the accommodation portion exists in the vicinity of the operated hand. Opening can be performed easily. Further, since the container is opened near the entrance of the gap between the living tissue and the insertion member, the drug composition that has flowed out of the container immediately closes the gap between the living tissue and the insertion member, and is inserted. It is applied so as to cover the peripheral part of the part, and the risk of infection and inflammation can be greatly reduced.
  • the insert is an indwelling needle having an outer needle as the insertion member and a catheter hub as the large diameter portion, the effect of the previous item is effectively exhibited and a smooth procedure is performed. It can be done easily.
  • the drug composition is colored, when inserting the insert, the drug composition itself becomes a kind of guide, and the range of the puncture portion of the insert and the sealing condition are visually confirmed. The procedure can be performed smoothly and reliably.
  • the guide part for guiding the flow of the pharmaceutical composition is provided so that the pharmaceutical composition flows down the gap through the insertion body, the smoothness of the pharmaceutical composition from the housing part to the gap is provided. And can be applied easily and quickly.
  • FIG. 1 is a partially broken schematic front view showing a first embodiment of the present invention
  • FIG. 2 is a schematic perspective view showing an operation state of the same embodiment.
  • inserts according to the present invention as will be exemplified later.
  • an indwelling needle will be described.
  • the indwelling needle 10 of the present embodiment has an outer needle portion 11 and an inner needle portion 15.
  • the outer needle portion (usually referred to as a catheter) 11 includes an outer needle hub (catheter hub) 12 constituting a large diameter portion, and an outer needle 13 made of a soft resin provided at the proximal end of the outer needle hub 12. It consists of and.
  • the outer needle hub 12 is preferably made of a transparent (colorless and transparent), colored transparent or translucent resin, which ensures internal visibility.
  • resin materials such as polyolefin such as copolymer, polyurethane, polyamide, polyester, polycarbonate, polybutadiene, polyvinyl chloride and the like can be mentioned.
  • the material of the outer needle 13 is preferably a resin material, in particular, a soft resin material, and specific examples thereof include, for example, a fluorine resin such as PTFE, ETFE, and PFA, an olefin resin such as polyethylene and polypropylene, or the like.
  • the outer needle 13 has internal visibility. That is, the outer needle 13 is preferably composed of a transparent (colorless and transparent), colored transparent or translucent resin. Thereby, when the outer needle 12 secures a blood vessel, a phenomenon (flashback) in which blood flows into the outer needle hub 12 through the inner needle 17 described later can be visually confirmed.
  • an X-ray contrast agent such as barium sulfate, barium carbonate, bismuth carbonate, tungstic acid, or an MRI visualizing agent such as gadolinium salt is blended to provide a contrast function.
  • an X-ray contrast agent such as barium sulfate, barium carbonate, bismuth carbonate, tungstic acid, or an MRI visualizing agent such as gadolinium salt is blended to provide a contrast function.
  • the inner needle portion 15 is provided on the inner needle hub 16 provided in the central portion, the metal inner needle 17 provided on the proximal end side of the inner needle hub 16, and the distal end side of the inner needle hub 16.
  • the filter 18 and the filter cap 19 are formed.
  • the material of the inner needle hub 16 the same material as that of the outer needle hub 12 can be used.
  • the material of the inner needle 17 include a metal material such as stainless steel, aluminum or an aluminum alloy, titanium or a titanium alloy.
  • the indwelling needle 10 is usually stored and stored in a sealed case (not shown) with the inner needle 17 inserted into the outer needle 13.
  • the indwelling needle 10 When the indwelling needle 10 is used, it is performed as follows. First, the indwelling needle 10 with the inner needle 17 inserted into the outer needle 13 is punctured into the living body. Then, by removing only the inner needle 17, the outer needle 13 is left in the living body, and then, for example, when performing infusion, the infusion tube is connected to the outer needle hub 12.
  • the outer needle 13 placed in the living body has a gap between the living body and the outer needle 13.
  • the indwelling needle 10 of this embodiment has an antibacterial property against a living tissue and fluidity in the indwelling needle 10 of this embodiment so that the pharmaceutical composition Y1 is applied to the gap.
  • a bag-like bag (corresponding to a housing part) B in which a pharmaceutical composition Y1 is also enclosed.
  • the bag B is provided with at least a weak seal portion (corresponding to the opening portion) J having a different sealing strength, and the weak seal portion J of the bag B is ruptured to remove the pharmaceutical composition Y1 from the outer needle. It is made to flow out toward the gap between the part 11 and the living tissue.
  • a bag B for storing the pharmaceutical composition Y1 is provided on the distal end side of the outer needle hub 12 in the outer needle portion 11 (the distal end portion of the catheter hub formed larger in diameter than the outer needle 13).
  • the outer needle 13 is inserted obliquely from above with respect to the surface of the living body and is left in an inclined state.
  • the outer needle 13 is basically inserted into the living body up to the vicinity of the outer needle hub 12 (the tip of the catheter hub). Therefore, when the bag B is provided on the upper part of the outer needle hub 12 which is a position near the hand in the state after the insertion, the user inserts the bag B after inserting the outer needle 13 into the living body. It becomes easy to apply the pressing force P for the bursting operation.
  • the position where the bag B is provided is not necessarily limited to the upper portion of the outer needle hub 12 (catheter hub tip), but may be a side portion or a lower portion, an intermediate position between the upper portion and the side portion, Any position may be provided as long as it is located on the outer needle hub 12 and can flow out the pharmaceutical composition Y1 on the outer circumference of the catheter.
  • the bag B may be configured to be detachable from the outer needle portion 11. In such a configuration, after inserting the outer needle part 11 into the living body, an operation of causing the bag B to be attached to the outer needle part 11 and causing the drug composition Y1 to flow out may be performed, or the drug composition Y1 may be discharged.
  • the bag B may be attached to the outer needle portion 11 before performing the operation.
  • the drug composition Y1 flows out from the bag B as shown by an arrow in FIG.
  • the pharmaceutical composition Y1 flows from the outer needle hub 12 along the outer needle 13 due to gravity, and is directed to the gap between the living body and the outer needle 13. Since the pharmaceutical composition Y1 has not only fluidity but also antibacterial properties, it closes the gap between the living tissue and the insertion member, and covers the peripheral portion of the insertion portion, greatly increasing the risk of infection and inflammation. Can be reduced.
  • the user only needs to insert the outer needle 13 into the living body and apply a pressure P that ruptures the weak seal portion J of the bag B, and the gap between the outer needle 13 and the living tissue and the periphery of the insertion portion. Contamination of the part can be prevented by the pharmaceutical composition Y1.
  • the user since the user can perform the operation of inserting the outer needle 13 into the living body and the operation of rupturing the weakly sealed part J independently, the user can perform a desired operation after repeating the operation of inserting the outer needle 13. It becomes effective when set to the position of.
  • the pressure P for rupturing the weak seal portion J of the bag B can be arbitrarily set according to the use form, but places an excessive burden on the user by pressing with the user's hand.
  • the bag B is preferably set within a range in which the bag B can be opened without any problem.
  • it is set to about 0.1 to 5 N / 10 mm, particularly preferably about 0.3 to 3 N / 10 mm. can do.
  • the bag B may be formed very small together with the outer needle portion 11, but in such a case, it is difficult to apply the pressure P to the bag B by the user's hand, so that the bag B is easily pressed. Accordingly, an opening tool (not shown) for easily applying the pressure P to the bag B can be attached to and detached from the insert.
  • the pharmaceutical composition is not used wastefully or disappears, and after inserting and setting the outer needle 13, a predetermined amount of the pharmaceutical composition Y1 can be appropriately applied by one rupture operation. Is greatly improved. That is, as a device for applying the pharmaceutical composition Y1, a device that applies the pharmaceutical composition Y1 to the outer peripheral surface of the outer needle 13 is also conceivable. Compared with such a device, the pharmaceutical composition Y1 is used wastefully. The procedure can be performed well without being lost or lost.
  • the bag B for storing the drug composition Y1 may be any soft material as long as it has a property that does not react with the drug composition Y1. It is preferable that it contains.
  • a material for forming the flexible bag 2 particularly preferred are polyethylene or polypropylene, styrene-based thermoplastic elastomers such as styrene-butadiene copolymers and styrene-ethylene-butylene-styrene block copolymers, or ethylene-propylene copolymers. And those composed of a soft resin or the like softened by blending an olefinic thermoplastic elastomer such as ethylene-butene copolymer or propylene- ⁇ -olefin copolymer.
  • the bag B may be always attached to the outer needle 13 or may be formed independently and attached at the time of use. For example, when it is always attached, a known technique such as adhesion using an adhesive, fusion, or a method utilizing the tackiness of the material of the bag B itself can be used.
  • any pharmaceutical composition Y1 can be used as long as it closes the gap between the outer needle 13 and the living tissue when the outer needle 13 is inserted into the living body.
  • the pharmaceutical composition Y1 is preferably a liquid having fluidity because it travels along the outer needle 13 as described above, and has an appropriate adhesive property capable of closing the gap between the outer needle 13 and the living tissue. It is preferable that it is a chemical
  • the pharmaceutical composition Y1 may be composed of a bioabsorbable and degradable material. With such a material, when the outer needle 13 is indwelled in the living body, the adjustment of the indwelling period becomes unnecessary or the adjustment becomes easy.
  • composition Y1 examples include, for example, cyanoacrylate adhesives such as 2-octyl cyanoacrylate and 2-cyanoacrylate monomer, such as polyacrylamide, polyvinyl alcohol, polyvinyl ethyl ether, modified collagen, polyvinyl Examples include hydrogels such as pyrrolidone, gelatin, and hydroxyethyl methacrylate, and elastomers such as polyurethane, polyether urethane urea, silicone elastomer, polymethyl methacrylate, polyethylene glycol, and esters thereof.
  • cyanoacrylate adhesives such as 2-octyl cyanoacrylate and 2-cyanoacrylate monomer
  • polyacrylamide such as polyacrylamide, polyvinyl alcohol, polyvinyl ethyl ether, modified collagen, polyvinyl
  • hydrogels such as pyrrolidone, gelatin, and hydroxyethyl methacrylate
  • elastomers such as polyurethane,
  • Antibacterial agents added to this include, for example, penicillins, cephems, monobactams, carbapenems, aminoglycosides, new quinolones, macrolides, clindamycin, tetracyclines, metronidazole, ST mixtures, glycopeptides , Streptogramin, oxazolidinone, lipopeptide, glycylcycline, glycopeptide, chloramphenicol, ketolide and other antibacterial agents, nucleic acid protein synthesis inhibitors, pyridone carboxylic acid synthesis Antibacterial agents, folic acid metabolism inhibitors such as chlorhexidine, povidone iodine, iodine tincture, ethanol, isopropanol, isopropyl alcohol, oxidol and other antiseptics, and metal ions such as silver, copper, zinc and the like. What is necessary is just to select these suitably and accommodate in the bag B.
  • FIG. 3 is a main part schematic perspective view showing a second embodiment of the present invention
  • FIG. 4 is a main part schematic perspective view showing a modification of the same embodiment. In the present embodiment, as shown in FIG.
  • the bag B that stores the pharmaceutical compositions Y2 and Y3 is partitioned into a plurality of storage chambers R1 and R2 by the partition wall S, and the flow of the different properties in each of the storage chambers R1 and R2 Sexual drug compositions Y2 and Y3 are contained, two different drug compositions Y2 and Y3 are mixed by the rupture operation of the bag B, flow along the outer peripheral surface of the outer needle 13, and the outer needle 13 and the living tissue. I try to get into the gap between.
  • positioning of storage chamber R1, R2 separated by the partition S may be right and left of an axial direction, and may be up and down with respect to an axial line. It is not limited.
  • the drug composition is sealed in a single bag B, but in this embodiment, different drug compositions Y2 and Y3 are sealed in the respective storage chambers R, and both are mixed. And antibacterial properties, fluidity and adhesiveness.
  • a method for mixing the two is not particularly limited, and there is a method in which the partition wall S that separates the storage chamber R1 and the storage chamber R2 is connected by the weak seal portion J1.
  • examples of the pharmaceutical composition Y2 include high biocompatible polymers such as PEG and PVA having alginic acid, trilysine and ester active groups, or aldehyde groups
  • the pharmaceutical composition Y3 includes For example, a low molecular compound having Ca, PEG ester and an amine group, an imide group or the like, or a polymer having high biocompatibility such as PEG and PVA can be used.
  • FIG. 5 is a schematic perspective view showing a third embodiment of the present invention. As shown in FIG. 5, this embodiment is effective when the distal end portion 13 a of the outer needle 13 is scraped off so that the inclination angle ⁇ with respect to the axis X of the outer needle 13 becomes an acute angle.
  • the distal end portion 13a of the outer needle 13 is cut off, it is usually inserted into the living body with the slope of the distal end portion 13a facing up. Accordingly, when the bags B1 and B2 are provided at positions that face the upper and lower sides of the catheter hub 12, the bags B1 and B2 can be broken from the upper and lower sides and the internal drug compositions Y2 and Y3 can flow out during normal operation. B1 and B2 can be ruptured by a natural operation, and it becomes an easy-to-use device that can be used without feeling uncomfortable at the time of rupture.
  • an appropriate number of bags B may be provided corresponding to the number of drug compositions Y.
  • the drug composition Y may be all colored with a single color, and in some cases, the drug compositions Y2 and Y3 may be individually colored with a specific color.
  • the pharmaceutical composition Y when the pharmaceutical composition Y is colored, when the outer needle 13 is inserted, the pharmaceutical composition itself becomes a kind of standard, and the range of the puncture portion of the outer needle 13 and the sealing condition are visually confirmed. The procedure can be performed smoothly and reliably.
  • visualizing agents examples include vitamin colorants such as L-ascorbic acid (vitamin C), calcium L-ascorbate, and stearates, amaranth, erythrosine, allura red AC, new coxin, phloxine, acid red, tartrazine, sun Food colorants such as Set Yellow FCF, Fast Green, Carminic Acid, etc. are mentioned (fourth embodiment).
  • 6A to 6C are schematic perspective views showing the fourth embodiment of the present invention. This embodiment is different from the above-described embodiments in that the outer needle portion 11 constituting the insert is provided with a guide portion 14 for guiding the flow of the pharmaceutical composition.
  • the guide part 14 guides the flow of the drug composition so that the drug composition that has flowed out of the bag B travels along the outer needle part 11 and flows down toward the gap between the outer needle part 11 and the living tissue. It has the function to do.
  • outer needle hub 12 and the outer needle 13 are provided as separate bodies as the outer needle portion 11 according to the present embodiment and the two members are assembled, the outer needle portion 11 is shown as having an outer needle portion 11.
  • the needle portion 11 is not limited to such a configuration, and for example, an outer needle hub 12 and an outer needle 13 that are integrally manufactured in advance as shown in the above-described embodiments may be used.
  • the guide portion 14 can be constituted by, for example, a groove 14a provided at the tip of the outer needle hub 12 and a groove 14b provided in the outer needle 13.
  • the drug composition discharged from the bag B flows down along the groove 14a, and then flows down along the groove 14b.
  • the drug composition can flow more smoothly from the outer needle hub 12 to the outer needle 13.
  • the drug composition that has flowed into the groove 14 b flows out from the lower end of the groove 14 b and is guided to the gap between the living tissue and the outer needle portion 11.
  • the guide part 14 can be provided with a side wall 24 as shown in FIG. 6B, for example.
  • the side wall 24 prevents the drug composition from inadvertently flowing out of the grooves 14a and 14b when the drug composition flows down, and the drug composition drips or adheres to a site where application is not planned. Is prevented. Therefore, by providing the side wall 24 together with the guide portion 14, it is possible to apply the pharmaceutical composition in the gap between the living tissue and the outer needle portion 11 without waste.
  • a curved shape having a guide function can be imparted to a predetermined portion of the outer needle 13, and this portion can be made to function as the guide portion.
  • the curved portion constituting the guide portion 14 is formed so that the outer diameter gradually increases from the root portion of the outer needle 13 located on the outer needle hub 12 side toward the distal end side of the outer needle 13. be able to.
  • the pharmaceutical composition flowing down from the outer needle hub 12 flows down to the distal end side of the outer needle 13 via the guide portion 14 provided on the outer needle 13. At this time, the pharmaceutical composition flows down to the distal end side along the curved shape of the guide portion 14 and is guided to the gap between the living tissue and the outer needle portion 11.
  • the present invention is not limited to the above-described embodiments, and various modifications can be made by those skilled in the art within the technical idea of the present invention.
  • the outer needle of the indwelling needle has been described as the insert.
  • the present invention is not limited to this, and examples of the target of the insert include a blood vessel catheter, a urinary catheter, and a hard needle.
  • catheters such as an extramembranous catheter, or an indwelling needle, a Huber needle insertion part, an indwelling drain, a peritoneal dialysis tube, a cable of a biologically implantable medical device, and a tracheostomy cannula.
  • the present invention provides a medicine composition that has flowed out of a container provided in the insert, and flows down along at least a part of the insert, thereby forming a gap between the insert and the living tissue.
  • a medicine composition that has flowed out of a container provided in the insert, and flows down along at least a part of the insert, thereby forming a gap between the insert and the living tissue.
  • Each configuration can be changed as long as the function of guiding the pharmaceutical composition can be exhibited.
  • the form which utilized the bag-like bag was shown for the accommodating part which accommodates a pharmaceutical composition, the accommodating part changes as long as it has the function which can accommodate and hold
  • a container made of a hard or soft resin material can be used instead of the bag.
  • the opening part that opens the housing part can also be changed as long as the housing part has a configuration that can be opened, and instead of the weak seal part, for example, by a fitting cap, an operation such as pressing or pulling. It is possible to appropriately select from well-known members used for performing the outflow operation of fluid and fluid, such as a cap to be broken and a cap having a valve body provided with an opening / closing mechanism.
  • the present invention can be used as a drug composition application device for applying a drug in a gap between an insertion body inserted and placed in a living body and a living tissue and in a peripheral portion of the insertion portion.
  • 10 pharmaceutical composition application device, 11 ... outer needle part (insert) 12 ... Outer needle hub (large diameter part), 13 ... outer needle (insertion member), 14 ... Guide part, B (B1, B2) ... bag (accommodating part), J (J1, J2) ... weak seal part (opening part), R1, R2 ... containment chambers, S ... partition wall, Y (Y1, Y2, Y3) ... drug.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Cette invention concerne un dispositif d'administration d'une composition médicamenteuse capable de remplir efficacement un espace vide situé entre un corps introduit dans l'organisme et un tissu biologique au moyen d'une composition médicamenteuse, de manière à réduire, dans une large mesure, le risque d'infection et d'inflammation. La présente invention concerne, donc, un dispositif d'administration d'une composition médicamenteuse (10) capable d'assurer l'administration d'une composition médicamenteuse (Y) dans un espace vide situé entre un corps (11) introduit dans un organisme vivant et un tissu biologique, ledit dispositif se caractérisant en ce qu'il comprend le corps destiné à être introduit dans l'organisme (11), et une poche (B) contenant la composition médicamenteuse (Y) fluide et antibactérienne destinée à protéger les tissus biologiques, et en ce que la rupture de la poche (B) permet à la composition médicamenteuse (Y) de s'écouler dans ledit espace vide.
PCT/JP2012/055584 2011-03-29 2012-03-05 Dispositif d'administration d'une composition médicamenteuse Ceased WO2012132774A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013507313A JP5963744B2 (ja) 2011-03-29 2012-03-05 薬剤組成物塗布デバイス

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-073476 2011-03-29
JP2011073476 2011-03-29

Publications (1)

Publication Number Publication Date
WO2012132774A1 true WO2012132774A1 (fr) 2012-10-04

Family

ID=46930521

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/055584 Ceased WO2012132774A1 (fr) 2011-03-29 2012-03-05 Dispositif d'administration d'une composition médicamenteuse

Country Status (2)

Country Link
JP (1) JP5963744B2 (fr)
WO (1) WO2012132774A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106029156A (zh) * 2014-02-21 2016-10-12 阿瓦蒂姆技术股份有限公司 维护尿道导管的方法
JP2018506400A (ja) * 2015-01-22 2018-03-08 デブン エスピー ゼット オー オー 前立腺生検針
EP3164169A4 (fr) * 2014-07-01 2018-03-14 C.R. Bard Inc. Tampon d'interface hémostatique/antimicrobien destiné à être placé entre un dispositif médical placé par voie percutanée et la peau d'un patient
US10143799B2 (en) 2010-09-10 2018-12-04 C. R. Bard, Inc. Systems for isolation of a needle-based infusion set
US10525234B2 (en) 2010-09-10 2020-01-07 C. R. Bard, Inc. Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin
US10729846B2 (en) 2010-09-10 2020-08-04 C. R. Bard, Inc. Self-sealing pad for a needle-based infusion set
WO2022054859A1 (fr) * 2020-09-10 2022-03-17 テルモ株式会社 Objet médical allongé, et ensemble pour objet médical allongé

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507807A (ja) * 1991-05-29 1994-09-08 タベックス・インダストリーズ・インコーポレーテッド 留置カテーテル等用の防湿遮断層
JP2008220633A (ja) * 2007-03-13 2008-09-25 Alcare Co Ltd カテーテル固定具及びカテーテル固定具用パッド
JP2010088792A (ja) * 2008-10-10 2010-04-22 National Cardiovascular Center カフ部材及びカフ部材ユニット

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120289942A1 (en) * 2008-05-21 2012-11-15 Coloplast A/S Automatic barrier film removal
WO2011011023A1 (fr) * 2009-07-22 2011-01-27 C. R. Bard, Inc. Sonde intermittente hydrophile pré-mouillée et procédé pour son utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06507807A (ja) * 1991-05-29 1994-09-08 タベックス・インダストリーズ・インコーポレーテッド 留置カテーテル等用の防湿遮断層
JP2008220633A (ja) * 2007-03-13 2008-09-25 Alcare Co Ltd カテーテル固定具及びカテーテル固定具用パッド
JP2010088792A (ja) * 2008-10-10 2010-04-22 National Cardiovascular Center カフ部材及びカフ部材ユニット

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143799B2 (en) 2010-09-10 2018-12-04 C. R. Bard, Inc. Systems for isolation of a needle-based infusion set
US10525234B2 (en) 2010-09-10 2020-01-07 C. R. Bard, Inc. Antimicrobial/haemostatic interface pad for placement between percutaneously placed medical device and patient skin
US10729846B2 (en) 2010-09-10 2020-08-04 C. R. Bard, Inc. Self-sealing pad for a needle-based infusion set
US10806900B2 (en) 2010-09-10 2020-10-20 C. R. Bard. Inc. Insertion device with interface pad and methods of making
CN106029156A (zh) * 2014-02-21 2016-10-12 阿瓦蒂姆技术股份有限公司 维护尿道导管的方法
EP3164169A4 (fr) * 2014-07-01 2018-03-14 C.R. Bard Inc. Tampon d'interface hémostatique/antimicrobien destiné à être placé entre un dispositif médical placé par voie percutanée et la peau d'un patient
JP2018506400A (ja) * 2015-01-22 2018-03-08 デブン エスピー ゼット オー オー 前立腺生検針
US10660622B2 (en) 2015-01-22 2020-05-26 Debn Sp. Z O.O. Prostate biopsy needle
WO2022054859A1 (fr) * 2020-09-10 2022-03-17 テルモ株式会社 Objet médical allongé, et ensemble pour objet médical allongé
JPWO2022054859A1 (fr) * 2020-09-10 2022-03-17
JP7675086B2 (ja) 2020-09-10 2025-05-12 テルモ株式会社 医療用長尺体および医療用長尺体セット

Also Published As

Publication number Publication date
JP5963744B2 (ja) 2016-08-03
JPWO2012132774A1 (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
JP5963744B2 (ja) 薬剤組成物塗布デバイス
US11471245B2 (en) Intravascular line and port cleaning methods, methods of administering an agent intravascularly, methods of obtaining/testing blood, and devices for performing such methods
US8197749B2 (en) Methods for cleaning luer connectors
KR102047925B1 (ko) 누공 치료용 조성물
JP2562536B2 (ja) 感染予防されたカテーテル装置
US20090209907A1 (en) Single-Use Indicator For A Surgical Instrument And A Surgical Instrument Incorporating Same
US20070073248A1 (en) Trocar-cannula complex, cannula and method for delivering biologically active agents during minimally invasive surgery
JP2003530945A (ja) 殺菌医療手続装置及び実施方法
US20160287796A1 (en) Cartridge system to which a syringe body can be attached
EP2341864B1 (fr) Distributeur d'un fil de retraction dentaire
CN112912016A (zh) 双止回阀单手涂敷器
AU2003269597A1 (en) Catheter system and method for delivering medication to the bladder
AU2018200555A1 (en) Intravascular line and port cleaning methods, methods of administering an agent intravascularly, methods of obtaining/testing blood, and devices for performing such methods
JP2002224195A (ja) 輸液容器
RS61232B1 (sr) Špric za primenu koji sadrži sterilni rastvor sa medicinski aktivnom supstancom i postupak za pripremu istog
JP5856718B1 (ja) 輸液セット
JPWO2004093540A1 (ja) 遺体体液漏出防止装置
WO2016161062A1 (fr) Système d'aiguille hypodermique
US20230008738A1 (en) Three-way urology catheter stopcock and urology catheter stopcock assembly
JP2016514569A (ja) インラインカテーテルフラッシング用に改変された静脈内チュービングセット
DK2345450T3 (en) Application set, comprising an applicator and a hose-sheathing to the applicator, and implantationsinstrumenter
US20140074012A1 (en) Composition, system and method for tissue augmentation
JP2008255025A (ja) 遺体の処置装置
JP2012205696A (ja) 挿入部位封止体を備える挿入体
JP5013837B2 (ja) 遺体の処置装置

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12763391

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2013507313

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12763391

Country of ref document: EP

Kind code of ref document: A1